The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'June, 2020'. If you still can't find what you are looking for, try using the search box.
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.
Read the rest of entry »
OBN Members Hayes Parsons are supporting the wider community by providing clear and concise information regarding the pandemic from an insurance perspective.
A webinar tackling the challenges life science businesses face when preparing for the relaxation of lockdown and the possibility of welcoming their employees back to the office.
Oxford, UK - Nikalyte Ltd, a nanotechnology company developing equipment and applications for nanoparticle research, introduces the NL50, a first of its kind, benchtop vacuum nanoparticle system that generates ultra-pure and monodisperse nanoparticles in vacuum which are deposited straight onto the target substrate. The NL50 circumvents many of the problems faced when using solution and powder-based nanoparticles.
Executive search consultancy, Horton International UK, has announced the appointment of scientific recruitment heavyweight, Dafydd Wright, as Managing Partner.
Leaf Expression Systems (Leaf), announces that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic
This webinar forms part of of complimentary RSSL series following the launch of RSSL's sterility testing service and will guide you through the complexities around sterile products manufacturing, control, testing and release.
Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin. AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®
Unlock structure-based drug design of challenging projects.
For many biological targets of interest to pharma such as membrane proteins, structural information is difficult to obtain. The large size, complexity, and/or flexibility of these targets make them unsuitable for traditional structure determination techniques such as crystallography. Without structural insights to inform your drug design, you potentially miss out on discovering more effective drug candidates.
Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020. Abstract #231-OR will be available online from 14 June 2020
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.